Boustead Securities and FlashFunders client PetCure Oncology, LLC, a company providing veterinary cancer treatment utilizing noninvasive stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT), presented their new outcomes data and evidence-based treatment recommendations at the Veterinary Cancer Society's (VCS) Annual Conference held in Houston, TX on Friday, October 18th.
PetCure Oncology recently treated its 3,000th pet with advanced radiation therapy, reaching a historic milestone in the fast-growing field of veterinary radiation oncology.
View the full Preliminary Outcomes Data report here.
The presentation was delivered by Dr. Neal Mauldin, a triple-board certified veterinary specialist in radiation oncology, medical oncology and internal medicine, who leads PetCure’s team of seven board-certified veterinary radiation oncologists – one of the largest and most experienced in the country.
“We have now treated more than 3,000 pets on-protocol with radiation therapy, including more than 2,200 with stereotactic radiation,” explained Dr. Mauldin. “The good news is that many of them are still alive and thriving, so the data is still maturing. But objective analysis of the preliminary data at this point suggests that stereotactic radiation can be considered a standard of care for the treatment of many tumor types – much like it already is in human cancer treatment. This research is the least that PetCure Oncology can do for the many pet owners suffering with a cancer diagnosis.”
Nine of the 11 tumor types presented on Friday suggested increased median survival time for pets treated with stereotactic radiation (SRS/SRT) by PetCure Oncology relative to the current body of peer-reviewed published literature. The list includes some of the most common types of pet cancer, including brain tumors, nasal tumors, osteosarcoma (bone tumors), mast cell tumors, and melanoma.
While advanced radiation therapy, or stereotactic radiation (SRS/SRT), is still relatively new in veterinary medicine, the 3,000 pets treated on-protocol by PetCure Oncology represent an unprecedented source of data for clinical research. This research is scheduled to be followed by formal publication through peer-reviewed channels in 2020 and 2021.
To view the PetCure offering click here: https://www.flashfunders.com/petcure
This press release is not a solicitation or offer to buy or sell securities. Investments may be speculative, illiquid and carry a risk of loss. Past performance is not indicative of future results. There is no guarantee that any specific outcome will be achieved. Clinical trials may be in early stages.
About PetCure Oncology, LLC
Founded in 2014, PetCure Oncology’s mission is to provide pet families with support, knowledge and access to comprehensive and compassionate cancer care. PetCure Oncology has established a network of board-certified radiation oncologists and partnered with leading specialty animal hospitals across the country, providing a national network of comprehensive cancer centers with expertise in radiation oncology and stereotactic radiation (SRS/SRT), an advanced form of radiation therapy that may be effective in treating cancer. The first PetCure Oncology center opened in 2015 and the network aims to expand to seven centers in the fall of 2019 with additional sites under review. For more information, please visit www.petcureoncology.com
About Boustead Securities, LLC
Boustead Securities, LLC (“Boustead”) is an investment banking firm that executes and advises on IPOs, mergers and acquisitions, capital raises and restructuring assignments in a wide array of industries, geographies and transactions, for a broad client base. Boustead’s core value proposition is the ability to create opportunity through innovative solutions and tenacious execution. With experienced professionals in the United States, Boustead’s team moves quickly and provides a broad spectrum of sophisticated financial advice and services. Boustead is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. For more information, please visit www.boustead1828.com.
About Sutter Securities Group, Inc.
Headquartered in Irvine, California, Sutter Securities Group, Inc. (“SSG”), founded in 2013, through its affiliates, is an innovator and investment banking solutions provider. SSG owns and operates Sutter Securities Clearing, LLC, and Sutter Securities, Inc, FINRA member broker-dealers; Sutter Shareholder Services, LLC, a SEC-registered transfer agent; FlashFunders Funding Portal, LLC, a FINRA member funding portal; and Sutter Capital Management, Inc. SSG, through its affiliates, operates a U.S.-based online securities platform whose underlying technology and regulatory infrastructure are designed to enable issuers to engage in Regulation D, Regulation A (known as Reg A+), Regulation S, Regulation CF and fully registered S-1 and F-1 Initial Public Offerings in compliance with applicable federal, state and non-U.S. securities laws. SSG is a majority owned subsidiary of Boustead & Company Limited, a diversified non-bank financial institution. Additional information is available at www.flashfunders.com.
This announcement contains forward-looking statements. Forward-looking statements provide our current expectations or forecasts of future events. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements in this announcement include, but are not limited to, statements regarding our disclosure concerning the Company’s operations, cash flows, financial position and dividend policy.